| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Mickael Bonnan | |
| P2860 | cites work | Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis | Q21144285 |
| Neuronal antigens recognized by cerebrospinal fluid IgM in multiple sclerosis. | Q48570746 | ||
| Temporal and regional patterns of axonal damage following traumatic brain injury: a beta-amyloid precursor protein immunocytochemical study in rats. | Q48607800 | ||
| Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma | Q48720162 | ||
| Cortical demyelination and diffuse white matter injury in multiple sclerosis. | Q48726181 | ||
| The prognostic significance of cerebrospinal fluid in multiple sclerosis | Q48776568 | ||
| Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis | Q48873793 | ||
| Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab | Q48882820 | ||
| Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis | Q48949792 | ||
| Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients | Q82276225 | ||
| Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis | Q82694858 | ||
| Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS | Q83780130 | ||
| Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation | Q84431335 | ||
| Intrathecal levels of vitamin D and IgG in multiple sclerosis | Q84585375 | ||
| Free light chain monomers in the diagnosis of multiple sclerosis | Q85092576 | ||
| CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis | Q28244975 | ||
| Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro | Q28263099 | ||
| Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies | Q28282500 | ||
| Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord | Q28295737 | ||
| Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis | Q28727371 | ||
| Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis | Q28730755 | ||
| A study of oligoclonal band negative multiple sclerosis. | Q29544969 | ||
| Randomised double blind controlled trial of cyclosporin in multiple sclerosis | Q30495856 | ||
| Multiple sclerosis: T-cell receptor expression in distinct brain regions | Q33300045 | ||
| Cyclosporin A curtails the progression of free light chain synthesis in the CSF of patients with multiple sclerosis | Q33629204 | ||
| Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report | Q33732864 | ||
| Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. | Q34052870 | ||
| Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid recognizes identical epitopes over time | Q34073320 | ||
| A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis | Q34117793 | ||
| The neuropathological basis of clinical progression in multiple sclerosis | Q34188436 | ||
| Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). | Q34208618 | ||
| High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis | Q34237823 | ||
| Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis | Q34295012 | ||
| Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis | Q34538912 | ||
| Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients. | Q34577625 | ||
| Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica | Q34588283 | ||
| Widespread demyelination in the cerebellar cortex in multiple sclerosis. | Q34627051 | ||
| Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients | Q35149579 | ||
| Poly(I:C) promotes TNFα/TNFR1-dependent oligodendrocyte death in mixed glial cultures | Q35184144 | ||
| Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis. | Q35478956 | ||
| Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation | Q35480158 | ||
| Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. | Q35539775 | ||
| Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients | Q35585366 | ||
| Intrathecal effects of daclizumab treatment of multiple sclerosis | Q35635127 | ||
| Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results | Q35748459 | ||
| T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. | Q35828841 | ||
| Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis | Q35986699 | ||
| Tertiary lymphoid organ development coincides with determinant spreading of the myelin-specific T cell response | Q43887998 | ||
| Prospective study of multiple sclerosis with early onset | Q43980182 | ||
| Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration | Q44251663 | ||
| The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis | Q44342102 | ||
| Cladribine in treatment of chronic progressive multiple sclerosis | Q44496335 | ||
| Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study. | Q44869530 | ||
| Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients | Q44938493 | ||
| Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid | Q45172407 | ||
| Oligoclonal free kappa and lambda bands in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. An immunoaffinity-mediated capillary blot study | Q45293102 | ||
| MS and clinically isolated syndromes: shared specificity but diverging clonal patterns of virus-specific IgG antibodies produced in vivo and by CSF B cells in vitro | Q45384217 | ||
| Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy | Q45405778 | ||
| Intrathecal synthesis of virus-specific oligoclonal IgG, and of free kappa and free lambda oligoclonal bands in acute monosymptomatic optic neuritis. Comparison with brain MRI. | Q45756925 | ||
| Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis | Q45814039 | ||
| Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain | Q45854706 | ||
| Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring | Q46214595 | ||
| Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis | Q46266579 | ||
| The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study | Q47983430 | ||
| Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group | Q48180007 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial | Q48265627 | ||
| Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis | Q48276129 | ||
| The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis | Q48380906 | ||
| Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. | Q48427388 | ||
| CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone | Q48439741 | ||
| Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection. | Q36082102 | ||
| Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement | Q36163180 | ||
| Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis | Q36226307 | ||
| Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis | Q36351504 | ||
| B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation | Q36485715 | ||
| B cell exchange across the blood-brain barrier in multiple sclerosis | Q36498036 | ||
| Antimyelin antibody in multiple sclerosis: no change during immunosuppression | Q37055522 | ||
| Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone. | Q37200093 | ||
| Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis | Q37354974 | ||
| Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. | Q37445439 | ||
| Intrathecal methotrexate treatment in multiple sclerosis | Q37763624 | ||
| Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response | Q37874029 | ||
| B cells in multiple sclerosis: connecting the dots. | Q37943607 | ||
| B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms | Q38018052 | ||
| Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy | Q38061406 | ||
| The establishment of the plasma cell survival niche in the bone marrow | Q38070792 | ||
| Intrathecal immune reset in multiple sclerosis: exploring a new concept | Q38177901 | ||
| Does disease-irrelevant intrathecal synthesis in multiple sclerosis make sense in the light of tertiary lymphoid organs? | Q38198016 | ||
| Vitamin D effects on B cell function in autoimmunity | Q38206792 | ||
| B cell follicle-like structures in multiple sclerosis-with focus on the role of B cell activating factor. | Q38222302 | ||
| Targets of the humoral autoimmune response in multiple sclerosis | Q38238409 | ||
| MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. | Q38301511 | ||
| Relevance of immunological variables in neuroborreliosis and multiple sclerosis | Q38323751 | ||
| Intrathecal immunoglobulin synthesis in multiple sclerosis: effect of corticosteroids and azathioprine | Q38331530 | ||
| Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients | Q38348590 | ||
| Cyclosporine A suppresses immunoglobulin G biosynthesis via inhibition of cyclophilin B in murine hybridomas and B cells. | Q39451775 | ||
| Modifications of the cerebrospinal fluid IgG concentrations in patients with multiple sclerosis treated with intrathecal steroids | Q39528942 | ||
| Multiple sclerosis: The blood-brain-barrier and the measurement of de novo central nervous system IgG synthesis | Q39778417 | ||
| Schemes to eradicate the multiple sclerosis central nervous system immune reaction | Q39991518 | ||
| Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. | Q40637757 | ||
| Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values | Q40833195 | ||
| Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bands | Q41528645 | ||
| Oligoclonal restriction of antiviral immunoreaction in oligoclonal band-negative MS patients | Q42181305 | ||
| Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. | Q42181572 | ||
| Progression and CSF Inflammation after Eradication of Oligoclonal Bands in an MS Patient Treated with Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma. | Q42214758 | ||
| Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon | Q42583785 | ||
| Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients | Q42619341 | ||
| Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis | Q43004059 | ||
| Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration | Q43826251 | ||
| Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. | Q50979570 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. | Q51931426 | ||
| Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. | Q51973496 | ||
| Increased spontaneous immunoglobulin secretion associated with cyclophosphamide-induced immune suppression. | Q52493690 | ||
| Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis. | Q53221705 | ||
| Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome | Q53302766 | ||
| [Meningeal tertiary lymphoid organs: Major actors in intrathecal autoimmunity]. | Q53654095 | ||
| Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. | Q54445691 | ||
| Multiple sclerosis: measurement and validation of central nervous system IgG synthesis rate. | Q54519849 | ||
| Immune surveillance in multiple sclerosis patients treated with natalizumab. | Q54606407 | ||
| Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? | Q57041523 | ||
| Natalizumab effects on immune cell responses in multiple sclerosis | Q57041915 | ||
| Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis | Q60390368 | ||
| Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis | Q61230854 | ||
| Grey Matter Pathology in Multiple Sclerosis | Q61478750 | ||
| Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial | Q61642982 | ||
| Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation | Q64375533 | ||
| The long march of the cerebrospinal fluid profile indicative of clinical definite multiple sclerosis; and still marching | Q67980961 | ||
| Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study | Q68066027 | ||
| Azathioprine reduces intrathecal IgG synthesis in multiple sclerosis | Q69007813 | ||
| Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue | Q69049807 | ||
| Immunochemical estimation of IgG and albumin in cerebrospinal fluid | Q69373115 | ||
| Intrathecal synthesis of IgG, IgA, IgM and IgD in untreated multiple sclerosis and controls | Q69766813 | ||
| Therapeutic trials of multiple sclerosis and intrathecal IgG production | Q70142364 | ||
| Plasmapheresis in multiple sclerosis: preliminary findings | Q70532913 | ||
| Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis | Q70990140 | ||
| Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression | Q71689955 | ||
| Failure of intravenous and intrathecal cytarabine to modify central nervous system IgG synthesis in multiple sclerosis | Q71851128 | ||
| Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis | Q72077388 | ||
| Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients | Q72804921 | ||
| Multiple sclerosis de novo CNS IgG synthesis: effect of ACTH and corticosteroids | Q72866402 | ||
| Multiple sclerosis and intrathecal IgA synthesis | Q73233563 | ||
| MS and neuromyelitis optica in Martinique (French West Indies) | Q73550729 | ||
| Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment | Q78409843 | ||
| Specific antibody index in cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes | Q79577556 | ||
| Rituximab in a patient with multiple sclerosis--effect on B cells, plasma cells and intrathecal IgG synthesis | Q79930770 | ||
| CSF characteristics in early-onset multiple sclerosis | Q81041607 | ||
| Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis | Q81335025 | ||
| Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis | Q81401055 | ||
| 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis | Q81854480 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 296184 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Multiple Sclerosis International | Q26853855 |
| P1476 | title | Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments | |
| P478 | volume | 2015 |
| Q89531252 | Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS |
| Q39025444 | Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. |
| Q90286881 | Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS |
| Q55020429 | Estimation of intrathecal IgG synthesis: simulation of the risk of underestimation. |
| Q36564920 | Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis |
| Q92212758 | Molecular biomarkers in multiple sclerosis |
Search more.